127 related articles for article (PubMed ID: 35050740)
1. Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles.
Koopman B; van der Wekken AJ; Ter Elst A; Hiltermann TJN; Vilacha JF; Groves MR; van den Berg A; Hiddinga BI; Hijmering-Kappelle LBM; Stigt JA; Timens W; Groen HJM; Schuuring E; van Kempen LC
JCO Precis Oncol; 2020 Nov; 4():393-410. PubMed ID: 35050740
[TBL] [Abstract][Full Text] [Related]
2. Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Koopman B; Groen HJM; Ligtenberg MJL; Grünberg K; Monkhorst K; de Langen AJ; Boelens MC; Paats MS; von der Thüsen JH; Dinjens WNM; Solleveld N; van Wezel T; Gelderblom H; Hendriks LE; Speel EM; Theunissen TE; Kroeze LI; Mehra N; Piet B; van der Wekken AJ; Ter Elst A; Timens W; Willems SM; Meijers RWJ; de Leng WWJ; van Lindert ASR; Radonic T; Hashemi SMS; Heideman DAM; Schuuring E; van Kempen LC
Oncologist; 2021 Aug; 26(8):e1347-e1358. PubMed ID: 33111480
[TBL] [Abstract][Full Text] [Related]
3. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
[TBL] [Abstract][Full Text] [Related]
4. Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer Center.
Tögel L; Schubart C; Lettmaier S; Neufert C; Hoyer J; Wolff K; Moskalev EA; Stöhr R; Agaimy A; Reis A; Wullich B; Mackensen A; Pavel M; Beckmann MW; Hartmann A; Fietkau R; Meidenbauer N; Haller F; Spoerl S
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136436
[TBL] [Abstract][Full Text] [Related]
5. Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer.
Behel V; Noronha V; Choughule A; Shetty O; Chandrani P; Kapoor A; Bondili SK; Bajpai J; Kumar R; Pai T; Bal M; Gurav M; Bapat P; Mittal N; Menon S; Patil V; Menon N; Dutt A; Prabhash K
JCO Glob Oncol; 2022 Jul; 8():e2200030. PubMed ID: 35802838
[TBL] [Abstract][Full Text] [Related]
6. Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care.
Liu A; Vicenzi P; Sharma I; Orr K; Teller C; Koentz M; Trinkman H; Vallance K; Ray A
Hematol Rep; 2023 Apr; 15(2):244-255. PubMed ID: 37092519
[TBL] [Abstract][Full Text] [Related]
7. Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer Center.
Jain NM; Schmalz L; Cann C; Holland A; Osterman T; Lang K; Wiesner GL; Pal T; Lovly C; Stricker T; Micheel C; Balko JM; Johnson DB; Park BH; Iams W
Oncologist; 2021 Nov; 26(11):e1962-e1970. PubMed ID: 34390291
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting.
VanderWalde A; Grothey A; Vaena D; Vidal G; ElNaggar A; Bufalino G; Schwartzberg L
J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33260805
[TBL] [Abstract][Full Text] [Related]
9. Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors.
Sotelo-Rodríguez C; Vallejo-Ardila D; Ruiz-Patiño A; Chamorro DF; Rodríguez J; Moreno-Pérez DA; Carranza H; Otero J; Vargas C; Archila P; Rojas L; Zuluaga J; Rubio C; Ordóñez-Reyes C; Garcia-Robledo JE; Mejía S; Jaller E; Arrieta O; Cardona AF
JCO Glob Oncol; 2024 Jan; 10():e2300011. PubMed ID: 38237094
[TBL] [Abstract][Full Text] [Related]
10. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer.
Ciliberto G; Canfora M; Terrenato I; Agnoletto C; Agustoni F; Amoroso L; Baldassarre G; Curigliano G; Delmonte A; De Luca A; Fiorentino M; Gregorc V; Ibrahim T; Lazzari C; Mastronuzzi A; Pronzato P; Santoro A; Scambia G; Tommasi S; Vingiani A; Giacomini P; De Maria R
J Exp Clin Cancer Res; 2022 Oct; 41(1):305. PubMed ID: 36245005
[TBL] [Abstract][Full Text] [Related]
11. Thoracic multidisciplinary tumor board routinely impacts therapeutic plans in patients with lung and esophageal cancer: a prospective cohort study.
Schmidt HM; Roberts JM; Bodnar AM; Kunz S; Kirtland SH; Koehler RP; Hubka M; Low DE
Ann Thorac Surg; 2015 May; 99(5):1719-24. PubMed ID: 25678503
[TBL] [Abstract][Full Text] [Related]
12. Molecular Tumour Board (MTB): From Standard Therapy to Precision Medicine.
Ballatore Z; Bozzi F; Cardea S; Savino FD; Migliore A; Tarantino V; Chiodi N; Ambrosini E; Bianchi F; Goteri G; Filosa A; Barbisan F; Bartoli E; Papa R; Berardi R
J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892804
[No Abstract] [Full Text] [Related]
13. Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board.
Dalton WB; Forde PM; Kang H; Connolly RM; Stearns V; Gocke CD; Eshleman JR; Axilbund J; Petry D; Geoghegan C; Wolff AC; Loeb DM; Pratilas CA; Meyer CF; Christenson ES; Slater SA; Ensminger J; Parsons HA; Park BH; Lauring J
JCO Precis Oncol; 2017; 2017():. PubMed ID: 30003184
[TBL] [Abstract][Full Text] [Related]
14. Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer.
Krause A; Stocker G; Gockel I; Seehofer D; Hoffmeister A; Bläker H; Denecke T; Kluge R; Lordick F; Knödler M
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1231-1240. PubMed ID: 35394231
[TBL] [Abstract][Full Text] [Related]
15. Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options.
Bitzer M; Ostermann L; Horger M; Biskup S; Schulze M; Ruhm K; Hilke F; Öner Ö; Nikolaou K; Schroeder C; Riess O; Fend F; Zips D; Hinterleitner M; Zender L; Tabatabai G; Beha J; Malek NP
JCO Precis Oncol; 2020; 4():. PubMed ID: 32923905
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Treatment Recommendations by Molecular Tumor Boards Worldwide.
Rieke DT; Lamping M; Schuh M; Le Tourneau C; Basté N; Burkard ME; Metzeler KH; Leyvraz S; Keilholz U
JCO Precis Oncol; 2018 Nov; 2():1-14. PubMed ID: 35135153
[TBL] [Abstract][Full Text] [Related]
17. Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board.
Bernhardt EB; Chamberlin MD; Gorlov IP; de Abreu FB; Bloch KJ; Peterson JD; Tsongalis GJ; Shirai K; Dragnev KH; Miller TW; Tafe LJ
Pract Lab Med; 2020 Aug; 21():e00174. PubMed ID: 32613070
[TBL] [Abstract][Full Text] [Related]
18. Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience.
Hoefflin R; Geißler AL; Fritsch R; Claus R; Wehrle J; Metzger P; Reiser M; Mehmed L; Fauth L; Heiland DH; Erbes T; Stock F; Csanadi A; Miething C; Weddeling B; Meiss F; von Bubnoff D; Dierks C; Ge I; Brass V; Heeg S; Schäfer H; Boeker M; Rawluk J; Botzenhart EM; Kayser G; Hettmer S; Busch H; Peters C; Werner M; Duyster J; Brummer T; Boerries M; Lassmann S; von Bubnoff N
JCO Precis Oncol; 2018; 2():. PubMed ID: 32913998
[TBL] [Abstract][Full Text] [Related]
19. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
Rodriguez-Rodriguez L; Hirshfield KM; Rojas V; DiPaola RS; Gibbon D; Hellmann M; Isani S; Leiser A; Riedlinger GM; Wagreich A; Ali SM; Elvin JA; Miller VA; Ganesan S
Gynecol Oncol; 2016 Apr; 141(1):2-9. PubMed ID: 27016222
[TBL] [Abstract][Full Text] [Related]
20. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.
de Jager VD; Timens W; Bayle A; Botling J; Brcic L; Büttner R; Fernandes MGO; Havel L; Hochmair MJ; Hofman P; Janssens A; Johansson M; van Kempen L; Kern I; Lopez-Rios F; Lüchtenborg M; Machado JC; Mohorcic K; Paz-Ares L; Popat S; Ryška A; Taniere P; Wolf J; Schuuring E; van der Wekken AJ
Lancet Reg Health Eur; 2024 Mar; 38():100838. PubMed ID: 38476742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
